Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Asia Biotech Invest 2017
14 slides from Proteomics International Laboratories's conference presentation, Mar 21, 2017
Slide 1: Corporate Presentation | Singapore, Hong Kong, Shanghai
Corporate Presentation | Singapore, Hong Kong, Shanghai Asia Biotech Invest | 21st, 23rd, 27th March 2017 Global leader in predictive diagnostics ASX: PIQ 1 Proteomics International Laboratories Ltd
Slide 2: Disclaimer & forward-looking statements
Disclaimer & forward-looking statements This Presentation is provided by Proteomics International Laboratories Ltd (PILL, the Company). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in deciding whether or no
Slide 3: PIQ corporate overview
PIQ corporate overview Capital Structure Shareholders ASX code PIQ Top 20 Shareholders 64.6% Shares on issue 59m Major Shareholders Lipscombe 27.5% Market capitalisation (@ 19c) $11.2m XYLO PL 10.6% Listed (@ 20c); raised $3m Apr 2015 Dunlop/Randolph Res PL 9.2% Placement/SPP (@ 24c); $2m Dec 2016 H
Slide 4: Introducing PIQ
Introducing PIQ Revenue generating company – Est'd 2001 Global leader & innovator in field of proteomics World’s first company to receive ISO 17025 laboratory accreditation for proteomics services Diversified business model World first diagnostic test at commercialisation stage Proven technology wit
Slide 5: A world leading predictive diagnostic test - PromarkerD
A world leading predictive diagnostic test - PromarkerD Without PromarkerD With PromarkerD 5 Proteomics International Laboratories Ltd
Slide 6: PromarkerD in brief
PromarkerD in brief Predictive diagnostic test for diabetic kidney disease The Problem International Diabetes Foundation estimates 415 million people globally have diabetes According to US Centre for Disease Control, 35% of adults with diabetes have chronic kidney disease; there is no early detectio
Slide 7: PromarkerD - routes to market
PromarkerD - routes to market Income streams licensing fees upfront payments royalties IVD = In Vitro Diagnostic CDx = Companion Diagnostic LDT = Laboratory Developed Test Market size Country Population Diabetes cases Deal NPV Dominican Republic 11m 505,700 US$1.5m Singapore 6m 541,600 Japan 1
Slide 8: PromarkerD: status
PromarkerD: status Stages Timing Platform technology established Predictive diagnostic study results Patents granted in USA & China Diagnostic test data published Independent market assessment Predictive test data published Due Q2 2017 Validation study results – 500 patient Due Q2 2017 Regional clin
Slide 9: Business model
Business model Three synergistic business areas Unifying “Promarker” platform technology - leverage & efficiency Diversified product portfolio - blue sky potential - medium term deal flow - existing cash flow 9 Proteomics International Laboratories Ltd
Slide 10: Why PIQ?
Why PIQ? Leveraged business model – Established revenue ~$1m per annum reduces burn, trending to cash flow positive – Analytics revenue grew 34% in 2016 Strong IP position – Patents granted in major jurisdictions for ground-breaking PromarkerD diagnostic Proven technology platform – Proof of concept
Slide 11: Please contact
Please contact Richard Lipscombe Managing Director T: +61 8 9389 1992 | E: [email protected] www.proteomicsinternational.com Greg Wood Financial Advisor, K S Capital M:+61 416 076 377 | E: [email protected] Susan Fitzpatrick-Napier Media Contact, Digital Mantra Group P: +61
Slide 12: Proteomics International Laboratories Ltd
12 Proteomics International Laboratories Ltd
Slide 13: Supplemental: Changing lives......
Supplemental: Changing lives...... DNA shapes our lives. The Human Genome Project, to map human DNA, was the single largest undertaking in the history of biological science. Completed in 2003 it was a US$4 billion international collaboration. Today, cumulative benefits are estimated at US$1 trillion
Slide 14: Supplemental: Board & management
Supplemental: Board & management Terry Sweet FAICD, Chairman Director of several listed companies over the past 30 years in both executive and non-executive capacities. Companies include XRF Scientific Ltd, where he was Managing Director for 4 years, Western Biotechnology Ltd, Heartlink Ltd, and Sci
Proteomics International Laboratories — Asia Biotech Invest 2017 on 6ix